Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C.

doi:10.1007/s00535-017-1405-3

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C.

Journal of gastroenterology - 1 Jun 2018

Maekawa Shinya, Sato Mitsuaki, Kuratomi Natsuhiko, Inoue Taisuke, Suzuki Yuichiro, Tatsumi Akihisa, Miura Mika, Matsuda Shuya, Muraoka Masaru, Nakakuki Natsuko, Amemiya Fumitake, Takano Shinichi, Fukasawa Mitsuharu, Nakayama Yasuhiro, Yamaguchi Tatsuya, Sato Tadashi, Sakamoto Minoru, Murakawa Miyako, Nakagawa Mina, Asahina Yasuhiro, Enomoto Nobuyuki

Abstract excerpt

BACKGROUND: Liver damage presented as alanine aminotransferase (ALT) elevation and high ALT-caused treatment discontinuation occurs with high frequency in Japanese patients receiving daclatasvir plus asunaprevir (DCV/ASV) therapy for hepatitis C virus (HCV) infection, and its mechanism is unknown. METHODS: A total of 247 Japanese patients consisting of two independent cohorts with genotype-1b HCV infection...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbamates

Share to Chemical and Drug Induced Liver Injury

Share to Glucuronosyltransferase

Share to Imidazoles

Share to Isoquinolines

Share to Pyrrolidines

Share to Sulfonamides

Source

Open in PubMed

Identifiers

PMID: 29094205
DOI: 10.1007/s00535-017-1405-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C.PMID 29094205Read ↗

Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.Semantic proximity Read ↗

Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan.Semantic proximity Read ↗

Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination.Semantic proximity Read ↗

High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.Semantic proximity Read ↗

Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.Semantic proximity Read ↗

The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.Semantic proximity Read ↗

Exposure-Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection.Semantic proximity Read ↗

Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C.Semantic proximity Read ↗

Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.Semantic proximity Read ↗

Asunaprevir for hepatitis C: a safety evaluation.Semantic proximity Read ↗

Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.Semantic proximity Read ↗

Daclatasvir + asunaprevir: first global approval.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.